What are you looking for?

Need help finding what you are looking for? Contact Us

Compare

Free Samples

Home Market Research Reports Pharmaceutical

Prescription Drugs

PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1880614

PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1880614

Tetracyclines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

PUBLISHED: October 20, 2025

PAGES: 186 Pages

DELIVERY TIME: Inquiry

ADD TO COMPARE

SELECT AN OPTION

The global tetracyclines market continues to expand steadily as bacterial infection rates rise and pharmaceutical manufacturers introduce advanced, resistance-focused formulations. According to the latest data, the market was valued at USD 3.21 billion in 2024, is expected to reach USD 3.32 billion in 2025, and further grow to USD 4.45 billion by 2032, progressing at a CAGR of 4.3% during the forecast period. In 2024, North America led the global market with a 38.32% share, driven by high prescription volumes, advanced healthcare systems, and strong penetration of branded and generic antibiotic products.

Tetracyclines form a broad-spectrum antibiotic class comprising first-generation, second-generation, and third-generation formulations. These drugs treat a wide range of infections, including pneumonia, Chlamydia, rickettsial diseases, rosacea, pelvic inflammatory disease, Mycoplasma pneumoniae-associated illnesses, and several skin and soft tissue infections. The global resurgence of bacterial infections, combined with ongoing antimicrobial resistance challenges, continues to elevate the medical importance of tetracyclines.

A key factor driving market growth is the increasing prevalence of infectious diseases, particularly respiratory infections, skin infections such as acne and rosacea, and sexually transmitted diseases like Chlamydia. WHO data indicates that an estimated 128.5 million new Chlamydia infections occurred globally. Additionally, the National Rosacea Society reports that over 415 million people worldwide suffer from rosacea-conditions that significantly promote the demand for tetracycline antibiotics across hospitals, clinics, and retail pharmacies.

Another strong contributor to market expansion is the growing approval and availability of generic tetracycline products, making treatments more affordable and widely accessible. In April 2024, Lupin launched the first generic version of Oracea (Doxycycline 40 mg) in the U.S., reinforcing competitive pricing and improved patient access. Major players such as Pfizer Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories, and Lupin continue to strengthen their portfolios through launches, approvals, and R&D investments.

However, product recalls remain a significant market restraint. Manufacturing defects-such as dissolution issues, particulate contamination, and formulation inconsistencies-have resulted in multiple recalls, damaging brand credibility and imposing financial and regulatory burdens. Notable instances include the WHO alert for substandard tetracycline ophthalmic ointment in 2023 and the FDA-led recall of Avet Pharmaceuticals' tetracycline capsules in 2020.

Despite challenges, substantial opportunities arise from the growing development of novel tetracyclines designed to counter antimicrobial resistance. With rosacea and acne cases rising, pharmaceutical companies are focusing on next-generation tetracyclines with improved efficacy and safety. In March 2024, Journey Medical Corporation secured FDA approval for Emrosi (Minocycline ER, 40 mg), demonstrating superior outcomes for rosacea. Such advances address unmet clinical needs and open new therapeutic avenues.

An emerging trend boosting the market is the investigation of tetracyclines as potential anti-cancer agents. Research at the University of Osaka in 2024 revealed that minocycline can stimulate immune responses against cancer cells by targeting galectin-1, highlighting the potential repositioning of older antibiotics for oncology applications.

From a segmentation perspective, third-generation tetracyclines dominated the market in 2024 due to enhanced activity against resistant bacteria and improved tolerability. Skin infections accounted for the largest application segment, supported by increasing incidence of ABSSSIs, acne, and rosacea, alongside expanding drug approvals for ABSSSI treatment. The oral route of administration held the largest share owing to convenience, strong patient compliance, and new oral generic launches such as Pylera's generic formulation launched in 2023.

By distribution channel, retail pharmacies remained dominant in 2024, driven by high outpatient antibiotic prescriptions, including 27.1 million tetracycline prescriptions dispensed in the U.S. alone. Meanwhile, hospital pharmacies gained traction due to increasing hospitalization for severe infections, and online pharmacies recorded the fastest growth due to the rise of digital healthcare.

Regionally, North America generated USD 1.23 billion in 2024, maintaining clear dominance due to high disease prevalence and advanced antibiotic stewardship programs. Europe continues to grow with strong product approvals, while Asia Pacific is set to witness the fastest CAGR due to large patient populations and expanding generic drug availability. Latin America and the Middle East & Africa show moderate growth fueled by expanding healthcare infrastructure and rising awareness.

With the market advancing from USD 3.21 billion in 2024 to USD 4.45 billion by 2032, the tetracyclines market remains resilient, driven by expanding clinical applications, new product launches, and growing focus on combating antimicrobial resistance.

Segmentation By Generation

First Generation
Second Generation
Third Generation

By Application

Respiratory Infections
Gastrointestinal Tract Infections
Skin Infections
Others

By Route of Administration

Oral
Parenteral
Others

By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

By Geography

North America (By Generation, Application, Route of Administration, Distribution Channel, and Country)
- U.S.
- Canada
Europe (By Generation, Application, Route of Administration, Distribution Channel, and Country/Sub-region)
- U.K.
- Germany
- France
- Italy
- Spain
- Scandinavia
- Rest of Europe
Asia Pacific (By Generation, Application, Route of Administration, Distribution Channel, and Country/Sub-region)
- Japan
- China
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
Latin America (By Generation, Application, Route of Administration, Distribution Channel, and Country/Sub-region)
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa (By Generation, Application, Route of Administration, Distribution Channel, and Country/Sub-region)
- GCC
- South Africa
- Rest of the Middle East & Africa

Product Code: FBI113860

Table of Content

1. Introduction

1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends

4. Key Insights

4.1. Prevalence of Key Diseases- by Key Countries/Regions, 2024
4.2. Pipeline Analysis, by Key Players
4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
4.4. Regulatory & Reimbursement Scenarios, By Key Countries/ Regions

5. Global Tetracyclines Market Analysis, Insights and Forecast, 2019-2032

5.1. Market Analysis, Insights and Forecast - By Generation
- 5.1.1. First Generation
- 5.1.2. Second Generation
- 5.1.3. Third Generation
5.2. Market Analysis, Insights and Forecast - By Application
- 5.2.1. Respiratory Infections
- 5.2.2. Gastrointestinal Tract Infections
- 5.2.3. Skin Infections
- 5.2.4. Others
5.3. Market Analysis, Insights and Forecast - By Route of Administration
- 5.3.1. Oral
- 5.3.2. Parenteral
- 5.3.3. Others
5.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.4.1. Hospital Pharmacy
- 5.4.2. Retail Pharmacy
- 5.4.3. Online Pharmacy
5.5. Market Analysis, Insights and Forecast - Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America
- 5.5.5. Middle East & Africa

6. North America Tetracyclines Market Analysis, Insights and Forecast, 2019-2032

6.1. Market Analysis, Insights and Forecast - By Generation
- 6.1.1. First Generation
- 6.1.2. Second Generation
- 6.1.3. Third Generation
6.2. Market Analysis, Insights and Forecast - By Application
- 6.2.1. Respiratory Infections
- 6.2.2. Gastrointestinal Tract Infections
- 6.2.3. Skin Infections
- 6.2.4. Others
6.3. Market Analysis, Insights and Forecast - By Route of Administration
- 6.3.1. Oral
- 6.3.2. Parenteral
- 6.3.3. Others
6.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.4.1. Hospital Pharmacy
- 6.4.2. Retail Pharmacy
- 6.4.3. Online Pharmacy
6.5. Market Analysis, Insights and Forecast - By Country
- 6.5.1. U.S.
- 6.5.2. Canada

7. Europe Tetracyclines Market Analysis, Insights and Forecast, 2019-2032

7.1. Market Analysis, Insights and Forecast - By Generation
- 7.1.1. First Generation
- 7.1.2. Second Generation
- 7.1.3. Third Generation
7.2. Market Analysis, Insights and Forecast - By Application
- 7.2.1. Respiratory Infections
- 7.2.2. Gastrointestinal Tract Infections
- 7.2.3. Skin Infections
- 7.2.4. Others
7.3. Market Analysis, Insights and Forecast - By Route of Administration
- 7.3.1. Oral
- 7.3.2. Parenteral
- 7.3.3. Others
7.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.4.1. Hospital Pharmacy
- 7.4.2. Retail Pharmacy
- 7.4.3. Online Pharmacy
7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 7.5.1. Germany
- 7.5.2. U.K.
- 7.5.3. France
- 7.5.4. Italy
- 7.5.5. Spain
- 7.5.6. Scandinavia
- 7.5.7. Rest of Europe

8. Asia Pacific Tetracyclines Market Analysis, Insights and Forecast, 2019-2032

8.1. Market Analysis, Insights and Forecast - By Generation
- 8.1.1. First Generation
- 8.1.2. Second Generation
- 8.1.3. Third Generation
8.2. Market Analysis, Insights and Forecast - By Application
- 8.2.1. Respiratory Infections
- 8.2.2. Gastrointestinal Tract Infections
- 8.2.3. Skin Infections
- 8.2.4. Others
8.3. Market Analysis, Insights and Forecast - By Route of Administration
- 8.3.1. Oral
- 8.3.2. Parenteral
- 8.3.3. Others
8.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.4.1. Hospital Pharmacy
- 8.4.2. Retail Pharmacy
- 8.4.3. Online Pharmacy
8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 8.5.1. China
- 8.5.2. Japan
- 8.5.3. India
- 8.5.4. Australia
- 8.5.5. Southeast Asia
- 8.5.6. Rest of Asia Pacific

9. Latin America Tetracyclines Market Analysis, Insights and Forecast, 2019-2032

9.1. Market Analysis, Insights and Forecast - By Generation
- 9.1.1. First Generation
- 9.1.2. Second Generation
- 9.1.3. Third Generation
9.2. Market Analysis, Insights and Forecast - By Application
- 9.2.1. Respiratory Infections
- 9.2.2. Gastrointestinal Tract Infections
- 9.2.3. Skin Infections
- 9.2.4. Others
9.3. Market Analysis, Insights and Forecast - By Route of Administration
- 9.3.1. Oral
- 9.3.2. Parenteral
- 9.3.3. Others
9.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.4.1. Hospital Pharmacy
- 9.4.2. Retail Pharmacy
- 9.4.3. Online Pharmacy
9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 9.5.1. Brazil
- 9.5.2. Mexico
- 9.5.3. Rest of Latin America

10. Middle East & Africa Tetracyclines Market Analysis, Insights and Forecast, 2019-2032

10.1. Market Analysis, Insights and Forecast - By Generation
- 10.1.1. First Generation
- 10.1.2. Second Generation
- 10.1.3. Third Generation
10.2. Market Analysis, Insights and Forecast - By Application
- 10.2.1. Respiratory Infections
- 10.2.2. Gastrointestinal Tract Infections
- 10.2.3. Skin Infections
- 10.2.4. Others
10.3. Market Analysis, Insights and Forecast - By Route of Administration
- 10.3.1. Oral
- 10.3.2. Parenteral
- 10.3.3. Others
10.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.4.1. Hospital Pharmacy
- 10.4.2. Retail Pharmacy
- 10.4.3. Online Pharmacy
10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 10.5.1. GCC
- 10.5.2. South Africa
- 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

11.1. Global Market Share Analysis (2024)
11.2. Company Profiles
- 11.2.1. Pfizer Inc.
  - 11.2.1.1. Overview
  - 11.2.1.2. Generations
  - 11.2.1.3. SWOT Analysis
  - 11.2.1.4. Recent Developments
  - 11.2.1.5. Strategies
  - 11.2.1.6. Financials (Based on Availability)
- 11.2.2. Abbott
  - 11.2.2.1. Overview
  - 11.2.2.2. Generations
  - 11.2.2.3. SWOT Analysis
  - 11.2.2.4. Recent Developments
  - 11.2.2.5. Strategies
  - 11.2.2.6. Financials (Based on Availability)
- 11.2.3. Lupin
  - 11.2.3.1. Overview
  - 11.2.3.2. Generations
  - 11.2.3.3. SWOT Analysis
  - 11.2.3.4. Recent Developments
  - 11.2.3.5. Strategies
  - 11.2.3.6. Financials (Based on Availability)
- 11.2.4. Dr. Reddy's Laboratories Ltd.
  - 11.2.4.1. Overview
  - 11.2.4.2. Generations
  - 11.2.4.3. SWOT Analysis
  - 11.2.4.4. Recent Developments
  - 11.2.4.5. Strategies
  - 11.2.4.6. Financials (Based on Availability)
- 11.2.5. Everest Medicines
  - 11.2.5.1. Overview
  - 11.2.5.2. Generations
  - 11.2.5.3. SWOT Analysis
  - 11.2.5.4. Recent Developments
  - 11.2.5.5. Strategies
  - 11.2.5.6. Financials (Based on Availability)
- 11.2.6. Paratek Pharmaceuticals, Inc.
  - 11.2.6.1. Overview
  - 11.2.6.2. Generations
  - 11.2.6.3. SWOT Analysis
  - 11.2.6.4. Recent Developments
  - 11.2.6.5. Strategies
  - 11.2.6.6. Financials (Based on Availability)
- 11.2.7. Teva Pharmaceutical Industries Ltd.
  - 11.2.7.1. Overview
  - 11.2.7.2. Generations
  - 11.2.7.3. SWOT Analysis
  - 11.2.7.4. Recent Developments
  - 11.2.7.5. Strategies
  - 11.2.7.6. Financials (Based on Availability)
- 11.2.8. Sun Pharmaceutical Industries Ltd.
  - 11.2.8.1. Overview
  - 11.2.8.2. Generations
  - 11.2.8.3. SWOT Analysis
  - 11.2.8.4. Recent Developments
  - 11.2.8.5. Strategies
  - 11.2.8.6. Financials (Based on Availability)
- 11.2.9. Journey Medical Corporation
  - 11.2.9.1. Overview
  - 11.2.9.2. Generations
  - 11.2.9.3. SWOT Analysis
  - 11.2.9.4. Recent Developments
  - 11.2.9.5. Strategies
  - 11.2.9.6. Financials (Based on Availability)

Product Code: FBI113860

List of Tables

Table 1: Global Tetracyclines Market Revenue (USD billion) Forecast, by Generation, 2019-2032
Table 2: Global Tetracyclines Market Revenue (USD billion) Forecast, by Application, 2019-2032
Table 3: Global Tetracyclines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
Table 4: Global Tetracyclines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
Table 5: Global Tetracyclines Market Revenue (USD billion) Forecast, by Region, 2019-2032
Table 6: North America Tetracyclines Market Revenue (USD billion) Forecast, by Generation, 2019-2032
Table 7: North America Tetracyclines Market Revenue (USD billion) Forecast, by Application, 2019-2032
Table 8: North America Tetracyclines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
Table 9: North America Tetracyclines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
Table 10: North America Tetracyclines Market Revenue (USD billion) Forecast, By Country, 2019-2032
Table 11: Europe Tetracyclines Market Revenue (USD billion) Forecast, by Generation, 2019-2032
Table 12: Europe Tetracyclines Market Revenue (USD billion) Forecast, by Application, 2019-2032
Table 13: Europe Tetracyclines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
Table 14: Europe Tetracyclines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
Table 15: Europe Tetracyclines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
Table 16: Asia Pacific Tetracyclines Market Revenue (USD billion) Forecast, by Generation, 2019-2032
Table 17: Asia Pacific Tetracyclines Market Revenue (USD billion) Forecast, by Application, 2019-2032
Table 18: Asia Pacific Tetracyclines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
Table 19: Asia Pacific Tetracyclines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
Table 20: Asia Pacific Tetracyclines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
Table 21: Latin America Tetracyclines Market Revenue (USD billion) Forecast, by Generation, 2019-2032
Table 22: Latin America Tetracyclines Market Revenue (USD billion) Forecast, by Application, 2019-2032
Table 23: Latin America Tetracyclines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
Table 24: Latin America Tetracyclines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
Table 25: Latin America Tetracyclines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
Table 26: Middle East & Africa Tetracyclines Market Revenue (USD billion) Forecast, by Generation, 2019-2032
Table 27: Middle East & Africa Tetracyclines Market Revenue (USD billion) Forecast, by Application, 2019-2032
Table 28: Middle East & Africa Tetracyclines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
Table 29: Middle East & Africa Tetracyclines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
Table 30: Middle East & Africa Tetracyclines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

Figure 1: Global Tetracyclines Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
Figure 2: Global Tetracyclines Market Value Share (%), by Generation, 2024 & 2032
Figure 3: Global Tetracyclines Market Value Share (%), by Application, 2024 & 2032
Figure 4: Global Tetracyclines Market Value Share (%), by Route of Administration, 2024 & 2032
Figure 5: Global Tetracyclines Market Value Share (%), by Distribution Channel, 2024 & 2032
Figure 6: Global Tetracyclines Market Value Share (%), by Region, 2024 & 2032
Figure 7: North America Tetracyclines Market Value (USD billion), by Generation, 2024 & 2032
Figure 8: North America Tetracyclines Market Value Share (%), by Generation, 2024
Figure 9: North America Tetracyclines Market Value (USD billion), by Application, 2024 & 2032
Figure 10: North America Tetracyclines Market Value Share (%), by Application, 2024
Figure 11: North America Tetracyclines Market Value (USD billion), by Route of Administration, 2024 & 2032
Figure 12: North America Tetracyclines Market Value Share (%), by Route of Administration, 2024
Figure 13: North America Tetracyclines Market Value (USD billion), by Distribution Channel, 2024 & 2032
Figure 14: North America Tetracyclines Market Value Share (%), by Distribution Channel, 2024
Figure 15: North America Tetracyclines Market Value (USD billion), By Country, 2024 & 2032
Figure 16: North America Tetracyclines Market Value Share (%), By Country, 2024
Figure 17: Europe Tetracyclines Market Value (USD billion), by Generation, 2024 & 2032
Figure 18: Europe Tetracyclines Market Value Share (%), by Generation, 2024
Figure 19: Europe Tetracyclines Market Value (USD billion), by Application, 2024 & 2032
Figure 20: Europe Tetracyclines Market Value Share (%), by Application, 2024
Figure 21: Europe Tetracyclines Market Value (USD billion), by Route of Administration, 2024 & 2032
Figure 22: Europe Tetracyclines Market Value Share (%), by Route of Administration, 2024
Figure 23: Europe Tetracyclines Market Value (USD billion), by Distribution Channel, 2024 & 2032
Figure 24: Europe Tetracyclines Market Value Share (%), by Distribution Channel, 2024
Figure 25: Europe Tetracyclines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
Figure 26: Europe Tetracyclines Market Value Share (%), By Country/ Sub-region, 2024
Figure 27: Asia Pacific Tetracyclines Market Value (USD billion), by Generation, 2024 & 2032
Figure 28: Asia Pacific Tetracyclines Market Value Share (%), by Generation, 2024
Figure 29: Asia Pacific Tetracyclines Market Value (USD billion), by Application, 2024 & 2032
Figure 30: Asia Pacific Tetracyclines Market Value Share (%), by Application, 2024
Figure 31: Asia Pacific Tetracyclines Market Value (USD billion), by Route of Administration, 2024 & 2032
Figure 32: Asia Pacific Tetracyclines Market Value Share (%), by Route of Administration, 2024
Figure 33: Asia Pacific Tetracyclines Market Value (USD billion), by Distribution Channel, 2024 & 2032
Figure 34: Asia Pacific Tetracyclines Market Value Share (%), by Distribution Channel, 2024
Figure 35: Asia Pacific Tetracyclines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
Figure 36: Asia Pacific Tetracyclines Market Value Share (%), By Country/ Sub-region, 2024
Figure 37: Latin America Tetracyclines Market Value (USD billion), by Generation, 2024 & 2032
Figure 38: Latin America Tetracyclines Market Value Share (%), by Generation, 2024
Figure 39: Latin America Tetracyclines Market Value (USD billion), by Application, 2024 & 2032
Figure 40: Latin America Tetracyclines Market Value Share (%), by Application, 2024
Figure 41: Latin America Tetracyclines Market Value (USD billion), by Route of Administration, 2024 & 2032
Figure 42: Latin America Tetracyclines Market Value Share (%), by Route of Administration, 2024
Figure 43: Latin America Tetracyclines Market Value (USD billion), by Distribution Channel, 2024 & 2032
Figure 44: Latin America Tetracyclines Market Value Share (%), by Distribution Channel, 2024
Figure 45: Latin America Tetracyclines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
Figure 46: Latin America Tetracyclines Market Value Share (%), By Country/ Sub-region, 2024
Figure 47: Middle East & Africa Tetracyclines Market Value (USD billion), by Generation, 2024 & 2032
Figure 48: Middle East & Africa Tetracyclines Market Value Share (%), by Generation, 2024
Figure 49: Middle East & Africa Tetracyclines Market Value (USD billion), by Application, 2024 & 2032
Figure 50: Middle East & Africa Tetracyclines Market Value Share (%), by Application, 2024
Figure 51: Middle East & Africa Tetracyclines Market Value (USD billion), by Route of Administration, 2024 & 2032
Figure 52: Middle East & Africa Tetracyclines Market Value Share (%), by Route of Administration, 2024
Figure 53: Middle East & Africa Tetracyclines Market Value (USD billion), by Distribution Channel, 2024 & 2032
Figure 54: Middle East & Africa Tetracyclines Market Value Share (%), by Distribution Channel, 2024
Figure 55: Middle East & Africa Tetracyclines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
Figure 56: Middle East & Africa Tetracyclines Market Value Share (%), By Country/ Sub-region, 2024
Figure 57: Global Tetracyclines Market Share (%), By Company, 2024